Chakraborty A, Blum R A, Mis S M, Cutler D L, Jusko W J
Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo 14260, USA.
J Clin Pharmacol. 1999 Jun;39(6):624-35. doi: 10.1177/00912709922008137.
The pharmacokinetic and adrenal interactions of recombinant human interleukin-10 and prednisolone were examined in this open-label, randomized, four-way crossover study in 12 healthy adult male volunteers. Single doses of IL-10 (8 micrograms/kg s.c.), IL-10 with prednisone (15 mg p.o.), placebo with prednisone, or placebo were administered on four separate occasions with at least 3-week interceding washout periods. Measurements included plasma prednisone, prednisolone and cortisol, unbound prednisolone, and serum IL-10 concentrations. Pharmacokinetic parameters were determined using noncompartmental and model-fitting analysis, while area analysis and an indirect response model were used to assess cortisol dynamics. IL-10 exhibited prolonged serum concentrations owing to dual-absorption processes that were largely unaffected by prednisone. The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours. Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10. Both prednisolone and prednisolone/IL-10 caused marked suppression of cortisol concentrations with similar magnitude and IC50 values; however, IL-10 alone significantly increased the 24-hour AUC of cortisol by 20%. Thus, IL-10 and prednisolone do not interact in disposition or adrenal suppression to a clinically significant degree.
在这项开放标签、随机、四交叉研究中,对12名健康成年男性志愿者进行了重组人白细胞介素-10(IL-10)与泼尼松龙的药代动力学及肾上腺相互作用研究。在四个不同时间分别给予单剂量的IL-10(8微克/千克,皮下注射)、IL-10联合泼尼松(15毫克,口服)、安慰剂联合泼尼松或安慰剂,每次给药间隔至少3周的洗脱期。测量指标包括血浆泼尼松、泼尼松龙和皮质醇、游离泼尼松龙以及血清IL-10浓度。使用非房室分析和模型拟合分析确定药代动力学参数,同时采用面积分析和间接反应模型评估皮质醇动力学。由于双吸收过程,IL-10的血清浓度延长,且在很大程度上不受泼尼松的影响。Cmax值约为3纳克/毫升,tmax出现在7至9小时。泼尼松龙呈现快速的全身动力学,Cmax为235纳克/毫升,tmax为1.11小时,t1/2为2.54小时,未因IL-10而发生显著改变。泼尼松龙和泼尼松龙/IL-10均导致皮质醇浓度显著抑制,幅度和IC50值相似;然而,单独使用IL-10可使皮质醇的24小时AUC显著增加20%。因此,IL-10和泼尼松龙在处置或肾上腺抑制方面没有临床显著程度的相互作用。